BioCentury | Nov 10, 2017
Company News

iPharma gets rights to Boehringer's FAK inhibitor

...Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520...
...Boehringer will receive an undisclosed upfront payment and is eligible for milestones and royalties. BI 853520...
...GmbH, Ingelheim, Germany BioLineRx Ltd. (Tel Aviv:BLRX; NASDAQ:BLRX), Modi'in, Israel I-Bridge Capital, China Business: Cancer Chris Lieu BI 853520 BioLineRx...
BioCentury | Nov 3, 2017
Company News

iPharma gets rights to Boehringer's FAK inhibitor

...Boehringer Ingelheim GmbH (Ingelheim, Germany) granted iPharma Ltd. exclusive, worldwide rights to develop and commercialize BI 853520...
...Boehringer will receive an undisclosed upfront payment and is eligible for milestones and royalties. BI 853520...
...that iPharma plans to obtain global rights to additional assets "at or near clinical stages." Chris Lieu BI 853520 BioLineRx...
Items per page:
1 - 2 of 2